Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages 3911-3920

  Walker, Brian A ^a   Boyle, Eileen M ^a   Wardell, Christopher P ^a   Murison, Alex ^a   Begum, Dil B ^a   Dahir, Nasrin M ^a   Proszek, Paula Z ^a   Johnson, David C ^a   Kaiser, Martin F ^a   Melchor, Lorenzo ^a   Aronson, Lauren I ^a   Scales, Matthew ^a   Pawlyn, Charlotte ^a   Mirabella, Fabio ^a   Jones, John R ^a   Brioli, Annamaria ^a   Mikulasova, Aneta ^g   Cairns, David A ^b   Gregory, Walter M ^b   Quartilho, Ana ^b   Drayson, Mark T ^d   Russell, Nigel ^e   Cook, Gordon ^c   Jackson, Graham H ^f   Leleu, Xavier ^h   Davies, Faith E ^a   Morgan, Gareth J ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g MASARYK UNIVERSITY   (Czech Republic)

^h LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; B RAF KINASE; CYLD PROTEIN; DIS3 PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; FAM46C PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HIST1H1E PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; K RAS PROTEIN; LTB PROTEIN; MAX PROTEIN; N RAS PROTEIN; PROTEIN P53; RB1 PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; RAS PROTEIN;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COPY NUMBER VARIATION; CYTOGENETICS; DNA REPAIR; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SURVIVAL; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MUTATIONAL ANALYSIS; EPIDEMIOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; UNITED KINGDOM; YOUNG ADULT;

ADULT; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RAS PROTEINS; SURVIVAL ANALYSIS; UNITED KINGDOM; YOUNG ADULT;

EID: 84947116451     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.1503     Document Type: Article

References (56)

1. Morgan GJ, Walker BA, Davies FE: The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335-348, 2012
2. Boyd KD, Ross FM, Chiecchio L, et al: A novel prognostic model in myeloma based on cosegregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial Leukemia 26:349-355, 2012
3. Avet-Loiseau H., Durie BG, Cavo M, et al Combining fluorescent in situ hybridization data with SS staging improves risk assessment in myeloma An International Myeloma Working Group collaborative project. Leukemia 27:711-717, 2013
4. Klein U, Jauch A, Hielscher T., et al: Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 117:2136-2144, 2011
5. Greipp PR, San Miguel J, Durie BG, et al International staging system for multiple myeloma J Clin Oncol 23:3412-3420, 2005
6. Walker BA, Wardell CP, Johnson D.C., et al: Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 121: 3413-3419, 2013
7. Ross FM, Avet-Loiseau H, Ameye G., et al: Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97:1272-1277, 2012
8. Avet-Loiseau H., Attal M, Moreau P., et al: Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 109:3489-3495, 2007
9. Avet-Loiseau H., Li C, Magrangeas F., et al: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585-4590, 2009
10. Fonseca R, Blood E, Rue M., et al: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575, 2003
11. Walker BA, Wardell CP, Brioli A, et al: Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 4:e191, 2014
12. Walker BA, Wardell CP, Murison A, et al: APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun 6:6997, 2015
13. Jenner MW, Leone PE, Walker B.A., et al: Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110:3291-3300, 2007
14. Lohr JG, Stojanov P, Carter S.L., et al: Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell 25:91-101, 2014
15. Chapman MA, Lawrence MS, Keats J.J., et al: Initial genome sequencing and analysis of multiple myeloma. Nature 471:467-472, 2011
16. Bolli N, Avet-Loiseau H, Wedge D.C., et al: Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997, 2014
17. Kozarewa I, Rosa-Rosa JM, Wardell C.P., et al: A modified method for whole exome resequencing from minimal amounts of starting DNA. PLoS One 7:e32617, 2012
18. Boeva V, Popova T, Bleakley K., et al: Control-FREEC: A tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28:423-425, 2012
19. Rausch T, Zichner T, Schlattl A., et al: DELLY: Structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28: i333-i339, 2012
20. Kaiser MF, Walker BA, Hockley S.L., et al: A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia 27:1754-1757, 2013
21. Alpar D, de Jong D, Holczer-Nagy Z, et al: Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma. Genes Chromosomes Cancer 52:785-793, 2013
22. Schwab CJ, Jones LR, Morrison H, et al: Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 49:1104-1113, 2010
23. Boyle EM, Proszek P, Kaiser M., et al: A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes Cancer 64: 91-98, 2015
24. JAGS 3.4.0: Just Another Gibbs Sampler. http://mcmc-jags.sourceforge.net/
25. Nuijten M, Wetzels R, Matzke D., et al: Default Bayesian hypothesis tests for correlation, partial correlation, and mediation. http://cran.r-project.org/web/packages/BayesMed/BayesMed.pdf
26. Wetzels R, Wagenmakers EJ: A default Bayesian hypothesis test for correlations and partial correlations. Psychon Bull Rev 19:1057-1064, 2012
27. Kass R, Raferty A: Bayes factors. J Am Stat Assoc 90:773-795, 1995
28. Wei T: Visualization of a correlation matrix. http://cran.r-project.org/web/packages/corrplot/corrplot.pdf
29. R Development Core Team: R: A Language and Environment for Statistical Computing: R Foundation for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2013
30. Therneau T, Grambsch P: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer, 2000
31. Therneau T: Survival analysis. http://cran.rproject.org/web/packages/survival/survival.pdf
32. Hothorn T, Hornik K, van de Wiel M, et al: Implementing a class of permutation tests: The {coin} package. J Stat Software 28:1-23, 2008
33. Hothorn T, Hornik K, van de Wiel M, et al: A Lego system for conditional inference. Am Stat 60:257-263, 2006
34. Qiu W, Chavarro J, Lazarus R., et al: Power and sample size calculation for survival analysis of epidemiological studies. http://cran.r-project.org/web/packages/powerSurvEpi/powerSurvEpi.pdf
35. Harrell FE: Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer, 2001
36. Annunziata CM, Davis RE, Demchenko Y, et al: Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007
37. Chen L, Wang S, Zhou Y., et al: Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood 115:61-70, 2010
38. Foth M, Ahmad I, van Rhijn BW, et al: Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J Pathol 233: 148-158, 2014
39. Ronchetti D, Greco A, Compasso S., et al: Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4; 14): Comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20:3553-3562, 2001
40. Lode L, Eveillard M, Trichet V., et al: Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 95:1973-1976, 2010
41. Skowronska A, Austen B, Powell J.E., et al: ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica 97:142-146, 2012
42. Guarini A, Marinelli M, Tavolaro S., et al: ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 97: 47-55, 2012
43. Fang NY, Greiner TC, Weisenburger D.D., et al: Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA 100:5372-5377, 2003
44. Meier M, den Boer ML, Hall AG, et al: Relation between genetic variants of the ataxia telangiectasiamutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia 19:1887-1895, 2005
45. Austen B, Barone G, Reiman A., et al: Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients. Br J Haematol 142:925-933, 2008
46. Zighelboim I, Schmidt AP, Gao F, et al: ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol 27:3091-3096, 2009
47. Matsuoka S, Ballif BA, Smogorzewska A, et al: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160-1166, 2007
48. Mu JJ, Wang Y, Luo H., et al: A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints. J Biol Chem 282:17330-17334, 2007
49. Chudnovsky Y, Kim D, Zheng S., et al: ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep 6:313-324, 2014
50. Zhu YX, Braggio E, Shi C.X., et al: Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124:536-545, 2014
51. Boone DN, Qi Y, Li Z., et al: Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci USA 108:632-637, 2011
52. Wirth M, Stojanovic N, Christian J., et al: MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Res 42:10433-10447, 2014
53. Joslin JM, Fernald AA, Tennant T.R., et al: Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 110:719-726, 2007
54. Mulligan G, Lichter DI, Di Bacco A, et al: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123:632-639, 2014
55. Takahashi N, Yamada Y, Taniguchi H., et al: Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes 7:271, 2014
56. Bruce S, Leinonen R, Lindgren C.M., et al: Global analysis of uniparental disomy using high density genotyping arrays. J Med Genet 42:847-851, 2005